Innate Pharma (Innate Pharma) Cash-to-Debt : 2.32 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Innate Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 2.32.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Innate Pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Innate Pharma's Cash-to-Debt or its related term are showing as below:

IPHA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.32 Med: 14.08 Max: 62.84
Current: 2.32

During the past 13 years, Innate Pharma's highest Cash to Debt Ratio was 62.84. The lowest was 2.32. And the median was 14.08.

IPHA's Cash-to-Debt is ranked worse than
65.69% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs IPHA: 2.32

Innate Pharma Cash-to-Debt Historical Data

The historical data trend for Innate Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Innate Pharma Cash-to-Debt Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

11.69

7.95

2.71

2.40

2.32

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.71	2.84	2.40	2.19	2.32

Competitive Comparison of Innate Pharma's Cash-to-Debt

For the Biotechnology subindustry, Innate Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Cash-to-Debt falls into.

Innate Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Innate Pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	100.824	/	(9.745	+	33.759)
	=	2.32

Innate Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	100.824	/	(9.745	+	33.759)
	=	2.32

Innate Pharma (NAS:IPHA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Innate Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.